Author: The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

The major features of the European drug landscape have remained relatively stable in recent years. Drug use remains high by historical standards, but positive changes can be seen, with record levels of treatment provision accompanied by some signs of erosion in injecting, new heroin use, cocaine consumption and cannabis smoking. Any optimism, however, must be tempered by concerns that youth unemployment and service cuts could lead to the re-emergence of ‘old’ problems.

Moreover, a closer examination suggests that the drug situation may now be in a state of flux, with ‘new’ problems emerging that challenge current policy and practice models: new synthetic drugs and patterns of use are appearing, both on the illicit drug market and in the context of non-controlled substances.

Written by: Belinda Loring

This policy guidance aims to support European policy-makers to improve the design and implementation of policies to reduce inequities in alcohol-related harm. The WHO European Region has the highest level of alcohol consumption and alcohol-related harm in the world. Within European countries, the burden of alcohol-related harm falls more heavily upon certain groups. Reducing health inequities is a key strategic objective of Health 2020 – the European policy framework for health and well-being endorsed by the 53 Member States of the WHO European Region in 2012. This guide seeks to assist European policy-makers in contributing to achieving the objectives of Health 2020 in a practical way. It draws on key evidence, including from the WHO Regional Office for Europe’s Review of social determinants and the health divide in the WHO European Region. It sets out practical options to reduce the level and unequal distribution of alcohol-related harm in Europe, through approaches that address the social determinants of alcohol misuse and the related health, social and economic consequences.

Written by: Belinda Loring

This policy guidance aims to support European policy-makers to improve the design and implementation of policies to reduce inequities in tobacco-related harm. Smoking kills more Europeans than any other avoidable factor. Socioeconomic inequities in tobacco consumption in Europe are extensive, and are widening. The overall reduction in smoking in Europe has been a public health success, but the effects have mainly been seen in middle- and high-income groups, causing a substantial widening of inequities. Reducing health inequities is a key strategic objective of Health 2020 – the European policy framework for health and well-being endorsed by the 53 Member States of the WHO European Region in 2012. This guide seeks to assist European policy-makers in contributing to achieving the objectives of Health 2020 in a practical way. It draws on key evidence, including from the WHO Regional Office for Europe’s Review of social determinants and the health divide in the WHO European Region. It sets out options and practical methods to reduce the level and unequal distribution of tobacco use in Europe, through approaches that address the social determinants of tobacco use and the related health, social and economic consequences.

Authors: Ari Rosmarin and Niamh Eastwood (Release)

'A Quiet Revolution: Drug Decriminalisation Policies in Practice Across the Globe' is the first report to support Release's campaign 'Drugs - It’s Time for Better Laws'. This report looks at over 20 countries that have adopted some form of decriminalisation of drug possession, including some States that have only decriminalised cannabis possession. The main aim of the report was to look at the existing research to establish whether the adoption of a decriminalised policy led to significant increases in drug use - the simple answer is that it did not.
More information about the campaign can be accessed at:
www.release.org.uk/decriminalisation

Author: D. Thanki, J. Matias, P. Griffiths, A. Noor, D. Olszewski, R. Simon and J. Vicente (EMCDDA)

This report brings together, for the first time in Europe, an integrated overview of the prevalence of intensive cannabis use. Cannabis use is relatively common in the European Union (EU) and Norway, with around 23 million people (6.8 % of all 15- to 64-year-olds) having used the drug in the past year and about 12 million (3.6 % of all 15- to 64-year-olds) in the last month. Although the prevalence of last-year cannabis use among the general population is generally stable or decreasing in many countries, demands for treatment in which cannabis is the primary drug continue to rise, indicating a possible increase in related problems.